secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ginkgo Bioworks Holdings, Inc. (DNA)
CIK:        0001830214
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0000950170-22-014468
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ginkgo Bioworks appoints Kathy Hopinkah Hannan to its Board of Directors
------------------------------------------------------------------------

- Appointment effective August 2, 2022; term expires at 2023 annual meeting.
- Received options to purchase Class A common stock valued at $400,000 plus prorated RSUs and options.
- Eligible for $50,000 annual retainer and annual stock awards under Non-Employee Director Compensation Program.
- Hannan is retired KPMG Vice Chair and serves on boards of NLY, OTIS, and CRS.
- Board determined Dr. Hannan is independent under NYSE listing standards.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1830214/000095017022014468/0000950170-22-014468-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1830214/000095017022014468/dna-20220802.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-014468

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer